查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2022-2029 年全球 HIV/HBV/HCV 检测试剂盒市场
市场调查报告书
商品编码
1166508

2022-2029 年全球 HIV/HBV/HCV 检测试剂盒市场

Global HIV/HBV/HCV Test Kits Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

在预测期内 (2022-2029)，HIV/HBV/HCV 检测试剂盒的全球市场规模预计将以 6.8% 的复合年增长率增长。

HIV/HBV/HCV检测是定性检测和检测人血清、血浆和血液中的乙型肝炎表面抗原（HBsAg）和HIV-1、HIV-2、梅毒螺旋体（Tp）和HCV抗体。全血 HIV/HBV/HCV 检测用于定性检测和区分人血清、血浆和全血中的 HV-2、Tp 和 HCV 抗体。

市场动态

HIV/HBV/HCV 快速检测试剂盒的技术创新有望推动市场增长。

在合併感染率很高的撒哈拉以南非洲地区，HIV、HBV 和 HCV 感染的负担继续高得不成比例。 用于 HIV、HBV 和 HCV 血清学检测的高分析性能多重快速诊断方法有可能加强筛查级联并导致更具成本效益的护理联繫。 这种检测方法对难以接近的高危人群特别有用，并可能增加自我检测对公共卫生的影响。 例如，原型指尖全血三重 HIV/HCV/HBsAg 自检可以提供一种快速、廉价、无需工具且易于使用的方法来识别 HIV、HBV 和 HCV 感染。 特别是，它可能适用于改进撒哈拉以南非洲地区三种密切相关的地方病的筛查。 这些选择将增加筛查工作，降低因未确诊的 HIV、HBV 或 HCV 感染引起的疾病的未来成本，治疗这些感染，并支持根除 HCV 感染的努力。这是有可能的。 因此，预计上述因素将在预测期内推动市场。

人们对慢性乙型和丙型肝炎缺乏了解和认识预计会阻碍市场增长。

根据国家医学图书馆的说法，医疗保健提供者、社会服务提供者和公众并不知道乙型和丙型肝炎的传播。 缺乏对美国慢性病毒性肝炎流行的认识以及慢性乙型和丙型肝炎筛查和医疗管理的适当方法和目标可能导致持续传播，失去疫苗接种等预防机会，这很可能导致导致早期诊断和错失医疗机会，以及感染者健康状况的恶化。 因此，预计上述因素将在预测期内阻碍市场。

行业分析

HIV/HBV/HCV 测试套件市场根据各种行业因素（包括供应链分析、价格分析等）对市场进行深入分析。

COVID-19 影响分析

COVID-19 大流行对市场产生了一定程度的影响。 大流行扰乱了医疗保健系统，使提供基本临床护理、HIV/HBV/HCV 检测和治疗变得更加困难。 因此，在大流行期间未被诊断出患有 HIV、HBV 和 HCV 的人随后可能会被发现患有更晚期的疾病，从而导致发病率和死亡率增加。 根据世界卫生组织 (WHO) 的数据，2020 年有 10 个国家的乙肝检测中断，6 个国家的丙肝治疗中断，5 个国家的计划生育中断。 同样在 2020 年，作为 COVID-19 自身的大流行缓解措施的一部分，CDC 发布了关于推迟常规临床就诊和延迟非必要工作的指南。 该建议可让患者避免不必要的面对面咨询，并通过远程医疗、患者门户、电话、电子邮件等方式与医疗保健提供者进行沟通。 因此，COVID-19 大流行正在影响市场。 然而，这种情况预计将在预测期内逐渐改善。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第四章市场动态

  • 市场影响因素
    • 司机
      • HIV/HBV/HCV 快速检测试剂盒的技术创新有望推动市场增长。
    • 约束因素
      • 人们对慢性乙型肝炎和丙型肝炎缺乏了解和认识预计会阻碍市场增长。
    • 机会
    • 影响分析

第五章行业分析

  • 供应链分析
  • 定价分析

第 6 章 COVID-19 分析

  • COVID-19 市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按测试类型

  • 快速测试套件
  • 基于化验的测试套件

第 8 章按样本类型

  • 唾液
  • 血液
  • 尿液

第 9 章最终用户

  • 医院
  • 诊断实验室
  • 医务室
  • 政府机构、非政府组织
  • 其他

第10章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第11章竞争格局

  • 主要发展和战略
  • 公司股票分析
  • 值得关注的主要公司名单

第12章公司简介

  • F. Hoffmann-La Roche Ltd
    • 公司简介
    • 产品组合和内容
    • 主要亮点
    • 财务摘要
  • Bio-Rad Laboratories Inc.
  • Abbott Laboratories
  • Meridian Bioscience, Inc.
  • Biopanda Reagents Ltd
  • Nanjing Synthgene Medical Technology Co., Ltd.
  • AccuBioTech Co., Ltd.
  • BioMerieux SA
  • QIAGEN
  • Hologic Inc
  • Creative Diagnostics

第13章 HIV/HBV/HCV 检测试剂盒的全球市场-DataM

简介目录
Product Code: DMCD1250

Market Overview

The global HIV/HBV/HCV test kits market size was valued US$ YY million in 2021 and is expected to reach US$ XX million by 2029, growing at a CAGR of 6.8 % during the forecast period (2022-2029).

HIV/HBV/HCV test is a test of qualitative detection and differentiation of hepatitis B surface antigen (HBsAg) and antibodies to HIV-1, HIV-2, Treponema pallidum (Tp), and HCV in human serum, plasma, or whole blood.

Market Dynamics

Innovations in the HIV/HBV/HCV rapid test kits is expected to drive market growth.

In sub-Saharan Africa, where co-infection rates are high, the burden of HIV, HBV, and HCV infections continues to be disproportionately high. High analytical performance multiplex fast diagnostic procedures for HIV, HBV, and HCV serological testing may enhance the cascade of screening and result in more cost-effective linkage to care. Such a testing approach may be especially helpful for high-risk populations challenging to reach and may also boost the impact of self-testing on public health. For instance, The prototype finger-stick whole-blood Triplex HIV/HCV/HBsAg self-test may offer a quick, affordable, tool-free, and user-friendly method for identifying HIV, HBV, and HCV infections. It might be especially appropriate for improving the screening of three endemic viral illnesses closely related in sub-Saharan Africa. These options could increase screening efforts, lowering the future cost of diseases caused by undiagnosed HIV, HBV, or HCV infections and assisting with efforts to treat these infections and potentially eradicate HCV infection. Thus, from the above factors, the market is expected to drive in the forecast period.

Lack of knowledge and awareness about chronic hepatitis B and hepatitis C among people is expected to hamper the market growth.

According to the National Library of Medicine, healthcare providers, social-service providers, and the general public are unaware of hepatitis b&c infections. Lack of awareness about the prevalence of chronic viral hepatitis in the U.S., as well as the appropriate methods and target populations for screening and medical management of chronic hepatitis B and hepatitis C, most likely contributes to ongoing transmission; missed opportunities for prevention, including vaccination; missed opportunities for early diagnosis and medical care; and poor health outcomes in infected people. Thus, from the above-mentioned factors, the market is expected to get hampered in the forecast period.

Industry Analysis

The HIV/HBV/HCV test kits market provides in-depth analysis of the market based on various industry factors such as supply chain analysis, pricing analysis etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted the market. The pandemic has disrupted healthcare systems, making it more difficult to provide basic clinical care, HIV/HBV/HCV testing, and treatment. As a result, increased morbidity and mortality rates may result from those who had undiagnosed HIV, HBV, and HCV during the pandemic subsequently being found to have the disease in more advanced stages. Besides, according to the World Health Organisation, in 2020, 10 countries reported disruption in Hepatitis B testing, 6 in Hepatitis C Treatment initiation, and 5 in Family Planning. In addition, as part of the original COVID-19 pandemic mitigation initiatives, in 2020, the CDC published guidelines on deferring routine clinical visits and delaying non-essential operations. With this advice, patients avoid making unnecessary in-person visits and communicate with their healthcare practitioner via telemedicine, patient portals, phone, and email. Thus, the COVID-19 pandemic has affected the market. However, the situation is expected to improve gradually in the forecast period.

Segment Analysis

Assay Based Test Kits segment is expected to hold the largest market share in HIV/HBV/HCV test kits market

The assay-based test kits segment accounted for the largest market share in 2021. The segment benefits because these are the first line of patient tests. Moreover, healthcare professionals and patients in most developing regions rely on assay-based testing results. For instance, The HCV Ag assay has the advantages of being an immunoassay, not requiring the same time-consuming and costly sample processing as molecular diagnostics, and confirming current infection. Moreover, there have been innovations in assay-based test kits. For instance, One point-of-care test that uses the GeneXpert System is the Xpert HCV Viral Load Fingerstick Test from Cepheid. The finger-stick whole blood capillaries is examined for HCV RNA as part of this point-of-care test (or assay). This type of HCV testing involves taking capillary blood from the patient through a finger prick into a collection device called a Minivette, which is then processed in a GeneXpert device at or near the point-of-care testing location.

In addition, most patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex (ARC), as well as many asymptomatic people in high-risk groups, have been found to have antibodies to the human immunodeficiency virus (HIV). The existence of these HIV antibodies is frequently checked in human blood and plasma samples using enzyme-linked immunosorbent assays (ELISA). For instance, INNO-LIA HIV I/II Score is a Line Immuno Assay (LIA) that establishes the existence of antibodies against HIV-1, including group O and HIV-2 in human blood or plasma. The HIV I/II Score from INNO-LIA distinguishes between HIV-1 and HIV-2 infections. It is meant to be used in addition to an anti-HIV screening process on reactive specimens. Therefore, it has increased the demand for assay-based test kits. Thus, from the above factors, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

Middle East and Africa region holds the largest market share in the global HIV/HBV/HCV test kits market

In 2021, the Middle East and Africa accounted for the highest revenue share. The increasing prevalence of HIV, innovations in the HIV/HBV/HCV test kits, advancing guidelines for self-testing and well-established infrastructure in the region are some factors the market is expected to boost in the forecast period. For instance, according to the UNAIDS, in 2020, HIV prevalence in Eswatini was 26.8 %. HIV prevalence in Eswatini increased from 22.9 % in 2001 to 26.8 % in 2020, growing at an average annual rate of 0.84%. Moreover, new WHO guidelines strongly advise offering self-testing for the hepatitis C virus (HCV) as an alternate method to HCV testing facilities. On the occasion of the International AIDS Society Conference in 2021, WHO issued the updated guidelines-it is the first for HCV self-testing. The new guidelines highlight important factors that should be taken into account by national programs, service providers, and implementers of HCV testing. These factors for HCV self-testing include developing suitable and context-specific messages, service delivery models, and support tools through community engagement; creating effective pathways for people who self-test to obtain confirmatory testing and treatment or prevention services; educating providers; creating a supportive and enabling policy environment; and using quality-assured products. Besides, WHO has also developed technical specifications for prequalifying HCV self-testing products to ensure quality. Therefore, it has increased the demand for HIV/HBV/HCV test kits. Thus, from the above factors, the Middle East and Africa region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the HIV/HBV/HCV test kits market are F. Hoffmann-La Roche Ltd; Bio-Rad Laboratories Inc.; Abbott Laboratories; Meridian Bioscience, Inc.; Biopanda Reagents Ltd; Nanjing Synthgene Medical Technology Co., Ltd.; AccuBioTech Co., Ltd.; BioMerieux SA; QIAGEN; Hologic Inc; and Creative Diagnostics.

F. Hoffmann-La Roche Ltd:

Overview:

Hoffmann-La Roche Ltd is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. It is one of the largest biotech companies, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology, and neuroscience. It is a global leader in in-vitro and tissue-based cancer diagnostics and a frontrunner in diabetes management. Its personalized healthcare strategy aims to provide medicines and diagnostics that enable tangible improvements in patients' health, quality of life and survival. Moreover, Roche Molecular, one of four customer-focused areas of Roche Diagnostics Solutions, develops, manufactures and supplies a wide array of innovative molecular diagnostic products, tests, platforms and technologies used to identify and quantify DNA and RNA from different organisms.

Product Portfolio:

cobas MPX: The cobas MPX Test is a multi-dye, real-time PCR multiplex test for human immunodeficiency virus (HIV), hepatitis C virus (HCV) and hepatitis B virus (HBV) for use on the cobas 6800/8800 Systems. The single assay allows for simultaneous detection of three targets, improving efficiency and accuracy.

The global HIV/HBV/HCV test kits market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Innovations in the HIV/HBV/HCV rapid test kits are expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Lack of knowledge and awareness about chronic hepatitis B and hepatitis C among people is expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Test Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 7.1.2. Market Attractiveness Index, By Test Type Segment
  • 7.2. Rapid Test Kits*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Assay Based Test Kits

8. By Sample Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sample Type
    • 8.1.2. Market Attractiveness Index, By Sample Type Segment
  • 8.2. Saliva*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Blood
  • 8.4. Urine

9. By End user

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 9.1.2. Market Attractiveness Index, By End user Segment
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Diagnostic Laboratories
  • 9.4. Clinics
  • 9.5. Government Organizations and NGO's
  • 9.6. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sample Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sample Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sample Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sample Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sample Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. List of Key Companies to Watch

12. Company Profiles

  • 12.1. F. Hoffmann-La Roche Ltd*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Bio-Rad Laboratories Inc.
  • 12.3. Abbott Laboratories
  • 12.4. Meridian Bioscience, Inc.
  • 12.5. Biopanda Reagents Ltd
  • 12.6. Nanjing Synthgene Medical Technology Co., Ltd.
  • 12.7. AccuBioTech Co., Ltd.
  • 12.8. BioMerieux SA
  • 12.9. QIAGEN
  • 12.10. Hologic Inc
  • 12.11. Creative Diagnostics

LIST NOT EXHAUSTIVE

13. Global HIV/HBV/HCV Test Kits Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Applications
  • 13.3. Contact Us